InvestorsHub Logo
Followers 10
Posts 196
Boards Moderated 0
Alias Born 08/13/2013

Re: None

Wednesday, 06/10/2020 7:41:07 AM

Wednesday, June 10, 2020 7:41:07 AM

Post# of 60
Interesting point on IMU hotcopper (go to hotcopper for further review:)

https://hotcopper.com.au/threads/why-imu-is-a-multi-multi-bagger.5431324/

I have mentioned in previous posts i don’t believe the ASX market has attributed any value whatsoever to CF33 at current prices, or even at 10-12c for that matter.
We have a super impressive pipeline . “Game changing, paradigm shift, potentially disruptive to market leading blockbuster monoclonal antibodies and chemotherapy” , are the things being said.
A sum of the parts valuation today by any metric simply can not reasonably equal 3.5 for what has already been demonstrated to work!

HerVax + PD1 Vax+ CF33+ Mimitopes = US$ 100million! Seriously?

With HerVax the original Imugene product already advanced to halfway through Ph2 this is what the market is primarily focusing on and attributing current value.
How about attributing some realistic value for CF33.
Just look closely at the Oncolytic Virus landscape.
As four starting points ;